Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
516 articles
Novel payload technologies are reshaping antibody-drug conjugates, promising more precise and potent cancer therapies with fewer side effects.
A new review reveals how epithelial-to-mesenchymal transition fuels tumor invasion, immune evasion, and drug resistance through dynamic, reversible states.
Pyrroloquinoline quinone has demonstrated anticancer activity in preclinical studies, but human cancer trials remain absent. Here's where the science stands.
A tryptophan-derived gut metabolite suppresses colorectal cancer by blocking a key glycolysis enzyme via STAT3 inhibition.
A newly discovered bacteriophage inside common gut bacteria appears strongly linked to colorectal cancer, potentially explaining a long-standing medical paradox.
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
A sweeping 2025 review maps how gut, tumor, and systemic microbiomes promote or suppress cancer across every major tumor type.
A comprehensive review reveals how intracellular bacteria colonize cancer cells, fuel metastasis, and can be weaponized against tumors.
Engineered magnetotactic bacteria delivered orally penetrate colorectal tumors, trigger immune attack, and reshape gut microbial metabolism in mice.
A gut metabolite produced after chemo reprograms bone marrow immune cells, creating a lasting shield against colorectal cancer liver metastasis.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.
A Nature study reveals lung tumors activate vagal nerves to drive sympathetic signaling that shuts down anti-tumor immunity.
